suvemcitug

From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

Home
Ligands
suvemcitug

GtoPdb Ligand ID: 14397

Synonyms: BD-0801 | BD0801 | Enzeshu® (China)

suvemcitug is an approved drug

Compound class: Antibody

Comment: Suvemcitug (BD0801) is a humanized anti-VEGFA monoclonal antibody that was designed for anti-tumour action [1].

Summary
Biological activity
Clinical data
References

References
1. Yuan G, Lou G, Li J, Xu M, Liu X, Wang D, Zhang K, Zhu T, Li X, Huang Y et al.. (2026) Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial. Nat Cancer, 7 (1): 182-193. [PMID:41514054]

References

1. Yuan G, Lou G, Li J, Xu M, Liu X, Wang D, Zhang K, Zhu T, Li X, Huang Y et al.. (2026)
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.
Nat Cancer, 7 (1): 182-193. [PMID:41514054]